Temozolomide during and after radiotherapy for newly diagnosed glioblastomas: Aprospective multicenter study of Korean patients

Journal of Korean Neurosurgical Society

Volumn 52, Issue 2, 2012, Pages 92-97

  Joo, Jin Deok ^a   Chang, Jong Hee ^b   Kim, Jeong Hoon ^c   Hong, Yong Kil ^d   Kim, Young Hoon ^a   Kim, Chae Yong ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

Chemoradiotherapy; Glioblastoma; Korea; Temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EVALUATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; KOREA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN METHYLATION; RADIATION DOSE; SALVAGE THERAPY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84867055628     PISSN: 20053711     EISSN: 15987876     Source Type: Journal    
DOI: 10.3340/jkns.2012.52.2.92     Document Type: Article

References (20)

1. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, et al.: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12: 259-266, 2001
2. Chibbaro S, Benvenuti L, Caprio A, Carnesecchi S, Pulerà F, Faggionato F, et al.: Temozolomide as first-line agent in treating high-grade gliomas: phase II study. J Neurooncol 67: 77-81, 2004
3. Choi JW, Lee MM, Kim IA, Kim JH, Choe G, Kim CY: The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study. J Korean Neurosurg Soc 44: 222-227, 2008
4. DeAngelis LM: Brain tumors. N Engl J Med 344: 114-123, 2001
5. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, et al.: DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16: 3851-3857, 1998
6. Ishikawa E, Yamamoto T, Sakamoto N, Nakai K, Akutsu H, Tsuboi K, et al.: Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment. Neurol Med Chir (Tokyo) 50: 638-644, 2010
7. Jeon HJ, Kong DS, Park KB, Lee JI, Park K, Kim JH, et al.: Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. Clin Neurol Neurosurg 111: 679-682, 2009
8. Kim YH, Park CK, Cho WH, Kim IA, Moon S, Choe G, et al.: Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study. J Neurooncol 103: 503-512, 2011
9. Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, et al.: MGMT Gene Promoter Methylation as a Potent Prognostic Factor in Glioblastoma Treated with Temozolomide-Based Chemoradiotherapy: A Single-Institution Study. Int J Radiat Oncol Biol Phys: 2012. Inpress
10. Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, et al.: Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12: 289-296, 2010
11. Lakomý R, Fadrus P, Slampa P, Svoboda T, Kren L, Lzicarová E, et al.: [Multimodal treatment of glioblastoma multiforme: results of 86 consecutive patients diagnosed in period 2003-2009]. Klin Onkol 24: 112-120, 2011
12. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990
13. Omar AI, Mason WP: Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. Core Evid 4: 93-111, 2010
14. Park CK, Kim J, Yim SY, Lee AR, Han JH, Kim CY, et al.: Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neuro Oncol 13: 195-202, 2011
15. Siker ML, Chakravarti A, Mehta MP: Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Crit Rev Oncol Hematol 60: 99-111, 2006
16. Song KS, Phi JH, Cho BK, Wang KC, Lee JY, Kim DG, et al.: Long-term outcomes in children with glioblastoma. J Neurosurg Pediatr 6: 145-149, 2010
17. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al.: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375-1382, 2002
18. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005
19. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al.: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28: 1963-1972, 2010
20. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al.: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2000